Profil Institute for Clinical Research, Inc.'s Sr. Scientific Director Publishes Textbook on New and Emerging Therapeutics for Type 2 Diabetes

SAN DIEGO, June 4, 2013 /PRNewswire/ -- Profil Institute for Clinical Research, Inc., a center of excellence performing early phase diabetes, obesity and cardiometabolic clinical research, announced today a new textbook Drug Therapy for Type 2 Diabetes written by the company's Senior Scientific Director Andrew Krentz, M.D., and published by Springer Healthcare, a leading global scientific publisher. The book is available for pre-sale on Amazon.com and begins shipping on June 15, 2013.

The textbook presents detailed information about emerging and recently- introduced therapy options as well as established glucose-lowering drugs for type 2 diabetes. Most notably for physicians, the textbook provides guidance on tailoring drug regimens to the individual patient and integrating newer drugs into established treatment guidelines.

"Prof. Krentz's textbook will serve as a powerful resource for clinicians by compiling together the most relevant, practical and timely information available about emerging diabetes drug therapies and the integration of new drugs into existing treatment algorithms," said Prof. Ananda Basu of the Mayo Clinic. "It has been several years since a book with this content and format has been published. An up-to-date reference guide of this sort will help healthcare providers navigate the landscape of new and existing therapies to personalize effective treatment options for their patients with type 2 diabetes."

Prof. Krentz's research and clinical practice in diabetes, endocrinology and cardiovascular research spans more than three decades. He has published over 100 scientific articles on these topics, and, in addition to his latest textbook, is an author of a number of book chapters, including the well-regarded Textbook of Diabetes (Fourth Edition 2010). Prof. Krentz's previously published textbooks include Metabolic Syndrome & Cardiovascular Disease (2007) and Insulin Resistance: A Clinical Handbook (2002). He is also a co-author of a new textbook Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development: Focus On Early Phase Clinical Studies, to be published by Springer in early 2014.

As Senior Scientific Director at Profil Institute his research involves investigator-initiated research in diabetes and cardiometabolic therapies. Prof. Krentz also holds the position of Visiting Professor of Medicine at the Institute of Diabetes for Older People, Bedfordshire & Hertfordshire Postgraduate Medical School in the U.K. and is accredited as a clinical specialist by the European Hypertension Society.

Prof. Krentz serves on the editorial boards of several major scientific journals. He is Editor-in-Chief of Cardiovascular Endocrinology (www.cardiovascularendocrinology.com), an online scientific journal that publishes peer-reviewed research in cardiovascular disease, endocrinology, and metabolism with an emphasis on studies that demonstrate the interaction between these disciplines. The journal was recently named as a member of the HEART Group of international cardiovascular journals in the company of other top tier journals American Journal of Cardiology, Cardiology, Circulation, Circulation Research, European Heart Journal and Heart.

Prof. Krentz's was also recently invited to become a contributing member of the Geriatric Cardiology section of the 'Faculty of 1000'. This association of leading scientists and clinical researchers evaluates and publishes recommendations of peer-reviewed articles in 40 scientific disciplines and from globally recognized scientific journals. The Faculty includes 7 Nobel Prize winners, 81 fellows of The Royal Society, 12 Lasker Award winners, 146 members of the National Academy of Sciences and 104 members of the Institute of Medicine.

About Profil^® Institute for Clinical Research, Inc.

Profil Institute is internationally renowned as a Center of Excellence for early phase clinical research of drugs and devices for diabetes, obesity and cardiometabolic diseases. The company's scientific expertise, advanced metabolic clinical research methodologies, and automated glucose clamp technology enable Profil Institute to execute studies of far more complexity and have led Profil Institute to be the most highly regarded clinical research institute for early phase diabetes drug studies. Profil Institute has been involved with every clinically promising drug class in diabetes and in nearly 200 clinical studies since the company's inception in 2004. For more information, visit www.profilinstitute.com.

SOURCE Profil Institute for Clinical Research, Inc.